Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07214766 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
A Phase 1 study of Healthy Participants, sponsored by Genentech.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 312
- Enrollment target
- 4
- Study locations
NCT07214766: Recruiting Phase 1 study of Healthy Participants, sponsored by Genentech.
NCT07214766 is a Phase 1 study of Healthy Participants that is actively recruiting participants, run by Genentech. The registered enrollment target is 312 participants, above the 63-participant average among 119 other Healthy Participants trials with a reported enrollment target (395% higher). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07214766, a Phase 1 study of Healthy Participants, is actively recruiting participants, sponsored by Genentech.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 312 participants
- Enrollment target
- 4
- Study locations
Study Summary
This two-part study will evaluate the bioequivalence, safety, and tolerability of a single SC dose of trastuzumab administered via handheld syringe/syringe pump (HHS/SP) with infusion set (IS) and an on-body delivery system (OBDS).
Conditions Studied
Interventions
- DRUG Trastuzumab
Study Locations (4)
California
- Anaheim Clinical Trials - Anaheim
Florida
- Daytona Beach Clinical Rsch Unit - Daytona Beach
Missouri
- QPS Bio-Kinetic - Springfield
Texas
- Fortrea Clinical Research Unit - Dallas - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 312 participants |
| Start Date | 2025-10-17 |
| Est. Completion | 2026-04-15 |
| Phase | Phase 1 |
What NCT07214766 shows while recruiting
NCT07214766 is an interventional study that assigns participants to a tested intervention. The registered 312 participants enrollment target is mid-sized for trials with a published cap, above the 63-participant average among 119 other Healthy Participants trials with a reported enrollment target (395% higher).
The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 1 intervention - of which Trastuzumab is the first listed.
NCT07214766 reports a single indexed study location in California, Florida, Missouri.
Frequently Asked Questions
What is clinical trial NCT07214766 about?
NCT07214766 is a clinical study titled "A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants". This two-part study will evaluate the bioequivalence, safety, and tolerability of a single SC dose of trastuzumab administered via handheld syringe/syringe pump (HHS/SP) with infusion set (IS) and an on-body delivery system (OBDS).
What is the current status of trial NCT07214766?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 312 participants. The study started on 2025-10-17. Estimated completion is 2026-04-15.
What conditions does trial NCT07214766 study?
This clinical trial studies the following conditions: Healthy Participants.
What interventions are being tested in trial NCT07214766?
The interventions under investigation include: Trastuzumab (DRUG).
Who is sponsoring clinical trial NCT07214766?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07214766 being conducted?
This trial has 4 study locations across California, Florida, Missouri, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07214766's enrollment target sits among peer trials
312 4th of 119 higher than 116 of 119 other Healthy Participants trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Participants trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
-
Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04984551 · 312 participants · Phase 2
Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia
- NCT04999904 · 312 participants · NA
A Proprioceptive Training Program Using an Uneven Terrain Treadmill for Patients With Ankle Instability
- NCT05220332 · 312 participants · NA
Church-based Intervention to Improve Blood Pressure in African Americans
- NCT05434234 · 312 participants · Phase 1
A Study of YL201 in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI